Probiotics assist Alcoholic Cirrhosis
Research in UK suggests that supplements of friendly bacteria may restore the
immune function of white blood cells in alcoholics.
University College London researchers assigned
patients with alcoholic cirrhosis to receive Lactobacillus casei Shirota probiotics, and report that neutrophil (white blood cell) function was restored after four weeks.
"Our results provide novel data to suggest that Lactobacillus casei
Shirota may restore neutrophil dysfunction in alcoholic cirrhotic
patients," wrote lead author Vanessa Stadlbauer in the Journal of Hepatology.
The new study adds to the body of science by reporting that the
'friendly' bacteria may boost immune function in alcoholics.
"Previous studies have already reported benefits from probiotics for
the immune response, but no research has ever studied their
potential benefits in immune function of people with alcoholic
cirrhosis," say the researchers.
"Patients with alcoholic cirrhosis are susceptible to infections and
once infected, they have increased in-hospital mortality," explained
Stadlbauer and co-workers. "This may relate to a defective innate
immune response in conjunction with an inappropriate inflammatory
response."
Study details
The researchers recruited 20 people with alcoholic cirrhosis:
- 12 were assigned to consume L. casei Shirota supplements three
times a day for four weeks.
- The other eight were used as control subjects,(no Probiotics)
- a further 13 healthy people, also received no probiotics
As expected, the neutrophil phagocyte capacity was 25 per cent lower
in the people with alcoholic cirrhosis compared to the healthy
controls.
At the end of the study, however, this capacity was
normalized in the people receiving the probiotics.
No improvements
were observed in the alcoholic cirrhosis controls.
"Although our study was not randomised, the data from the
contemporaneous disease controls, who had similar clinical and
biochemical characteristics as the study group and showed no
significant changes in phagocytic function over the four-week study
period, lends weight to the suggestion that the observed
normalization in phagocytic capacity was likely to be due to an
effect of administration of Lactobacillus casei Shirota," wrote the
researchers.
The researchers suggest that the mechanism may be due to changes in
the secretion in interleukin 10 (IL-10), and also by affecting the
expression of the toll-like receptor (TLR4), which play a role in
activating the immune response.
"Further understanding of how Lactobacillus casei Shirota achieves
improved phagocytosis would provide novel insights into the
dysfunction of the innate immune system associated with alcoholic
cirrhosis and warrants an appropriately randomised, controlled and
powered clinical trial," concluded the researchers.
Reference:
Source: Journal of Hepatology (Elsevier) Published online 25 March 2008